The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
Open accessAbstract
BACKGROUND: Vascular endothelial growth factor action in tumour angiogenesis is well characterised; nevertheless, it functions as a key element in the promotion of the immune system's evasion by tumours. We sought to investigate the possible direct effect of VEGF on T-cell activation and through which type of VEGF receptor it exerts this effect on cells isolated from ovarian cancer patients' ascites. METHODS: T cells isolated from the ascites of ovarian cancer patients were cultured with anti-CD3 and IL-2, with or without VEGF for 14 days and the number of viable T cells was counted. Cytotoxic activity of cultured T cells and expression of VEGF receptor-2 (VEGFR-2), was assayed. RESULTS: The addition of VEGF in cultures significantly reduced the number and proliferation rate of T cells in a dose-dependent manner and CD3(+) T cells expressed VEGFR-2 on their surface upon activation. Experiments with specific anti-VEGFR-2 antibodies revealed that the direct suppressive effect of VEGF on T-cell proliferation is mediated by VEGFR-2. We also showed that VEGF significantly reduced the cytotoxic activity of T cells. CONCLUSION: Our study showed that ascites-derived T cells secrete VEGF and express VEGFR-2 upon activation. Vascular endothelial growth factor directly suppresses T-cell activation via VEGFR-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 481
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
Keck, M. K., Zuo, Z., Khattri, A., Stricker, T. P., Brown, C. D., Imanguli, M., Rieke, D., Endhardt, K., Fang, P., Brägelmann, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2481 · Cited by 370
Combination immunotherapy for hepatocellular carcinoma
Rimassa, L., Finn, R. S., & Sangro, B. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.003 · Cited by 359
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
Horikawa, N., Abiko, K., Matsumura, N., Hamanishi, J., Baba, T., Yamaguchi, K., Yoshioka, Y., Koshiyama, M., & Konishi, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0387 · Cited by 275
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00602-3 · Cited by 267
Zhou, Y., Ren, X., Hou, Z., Wang, N., Jiang, Y., & Luan, Y. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00480d · Cited by 165
γδ T Cells Promote Steatohepatitis by Orchestrating Innate and Adaptive Immune Programming
Torres‐Hernandez, A., Wang, W., Nikiforov, Y., Tejada, K., Torres, L., Kalabin, A., Adam, S., Wu, J., Lu, L., Chen, R., et al. (2020) · Hepatology · doi:10.1002/hep.30952 · Cited by 80
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65
Metadata
- Authors
- Gavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Ioannou, K., Ziogas, A. C., Rodolakis, A., Vlahos, G., Thomakos, N., Haidopoulos, D., Terpos, E., Antsaklis, A., Dimopoulos, M. A., & Bamias, A.
- Venue
- British Journal of Cancer
- Published
- 2012-11
- Volume
- 107
- Issue
- 11
- Pages
- 1869-1875
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1964871165
- Cited by
- 167
- References
- 1
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.